CDKN2A and neoplasm: Specifically, PDACs present significantly recurrent mutations, namely gain‐of‐function mutation in KRAS oncogene; loss‐of‐function mutations in CDKN2A, TP53 and SMAD4 tumor suppressor genes (Pompella et al. 2020).